Akari Therapeutics enters strategic ADC payload research collaboration with Whitehawk Therapeutics
AKTX•Strategic research collaboration with Whitehawk Therapeutics
Akari Therapeutics entered a strategic research collaboration with Whitehawk Therapeutics to evaluate its PH1 RNA splicing modulator ADC payload with Whitehawk’s TOP1i ADC platform.
Planned preclinical studies will test dual-payload combinations for synergy, aiming to generate data to support next-generation ADC development opportunities.
The partnership positions Akari’s PH1 platform for broader use beyond conventional ADC payload approaches as industry demand shifts toward differentiated payload innovation.
